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Abstract
Introduction: Although several studies have assessed plasma adipokines in patients treated with hypolipidemic agents, these studies 
have provided contrasting results. 
Material and methods: This study included 19 high-risk patients with elevated total and LDL cholesterol levels treated with simvastatin 
(40 mg daily) and ezetimibe (10 mg daily). Plasma levels of leptin, adiponectin, visfatin, tumour necrosis factor-α, free fatty acids as well 
as C-reactive protein were measured before and after 30 days of treatment. High-risk hypercholesterolemic patients were compared with 
17 age-, sex- and weight-matched healthy subjects who did not receive any treatment.
Results: Compared to the healthy subjects, hypercholesterolemic patients exhibited lower plasma levels of adiponectin, as well as higher 
plasma levels of the remaining adipokines. Administration of simvastatin and ezetimibe for 30 days reduced plasma levels of leptin, 
visfatin, TNF-α, as well as increased plasma levels of adiponectin. The treatment also reduced free fatty acids and C-reactive protein.
Conclusions: High-risk hypercholesterolemic patients with elevated cholesterol levels are characterised by abnormal production of adipose 
tissue hormones. Short-term treatment with simvastatin and ezetimibe partially restores adipokine production and inhibits low-grade 
inflammation. (Endokrynol Pol 2014; 65 (4): 275–280)
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Streszczenie
Wstęp: Chociaż w nielicznych badaniach oceniono uprzednio stężenie adipokin w osoczu chorych leczonych lekami hipolipemicznymi, 
jednak wyniki tych badań nie są zgodne. 
Materiał i metody: Badaniem objęto 19 pacjentów należących do grupy zwiększonego ryzyka schorzeń układu sercowo-naczyniowego, u których 
stwierdzono podwyższone stężenie cholesterolu całkowitego i cholesterolu LDL. U chorych tych zastosowano terapię skojarzoną, obejmującą 
podawanie simwastatyny (40 mg dziennie) i ezetimibu (10 mg dziennie). Stężenie w osoczu wybranych adipokin (leptyna, adiponektyna, 
wisfatyna oraz czynnik martwicy nowotworów α), wolnych kwasów tłuszczowych, jak również białka C-reaktywnego oceniano przed i po 
30 dniach leczenia. Badani pacjenci byli porównywani z grupą 17 zdrowych ochotników, dobranych pod względem wieku, płci i masy ciała.
Wyniki: W stosunku do grupy kontrolnej, u osób z hipercholesterolemią stwierdzono niższe stężenie w osoczu adiponektyny oraz wyższe 
stężenie w osoczu pozostałych adipokin. Trzydziestodniowe podawania simwastatyny z ezetimibem zmniejszyło stężenie leptyny, wis-
fatyny oraz czynnika martwicy nowotworów α, jak również zwiększyło stężenie adiponektyny. Spowodowało również spadek stężenia 
wolnych kwasów tłuszczowych i białka C-reaktywnego.
Wnioski: Pacjentów należących do grupy wysokiego ryzyka, u których stwierdza się hipercholesterolemię, charakteryzuje nieprawidłowe 
wytwarzanie hormonów tkanki tłuszczowej. Krótkotrwałe leczenie z zastosowaniem simwastatyny i ezetimibu częściowo przywraca 
prawidłowe wydzielanie adipokin i hamuje stan zapalny o niewielkim nasileniu. (Endokrynol Pol 2014; 65 (4): 275–280)
Słowa kluczowe: simwastatyna; ezetimib; hypercholesterolemia; leptyna; adiponektyna; wisfatyna; czynnik martwicy nowotworów α (TNF-α)
Abbreviations
CRP — C-reactive protein
FFA — free fatty acids 
HDL — high-density lipoprotein 
HMG-CoA — 3-hydroxy-3-methylglutaryl coenzyme A 
HOMA-IR —homeostatic model assessment of insulin 
resistance ratio 
hsCRP — high sensitivity C-reactive protein 
LDL — low-density lipoprotein 
TNF-α — tumour necrosis factor α
276
PR
A
C
E 
O
RY
G
IN
A
LN
E
Hypolipidemic therapy and adipokines   Robert Krysiak et al.
Introduction
Previous studies carried out in our laboratory have 
shown that combined therapy with a 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reductase 
inhibitor (statin) and an inhibitor of a Niemann-Pick 
C1-Like 1 transporter — ezetimibe — is associated 
with more pronounced changes in monocyte and 
lymphocyte cytokine release and in haemostasis than 
in the case of a statin and ezetimibe administered 
alone [1-3]. Unfortunately, the results of large clinical 
trials assessing the effects of the combined treatment 
with these agents are not so clear-cut. The effect of 
ezetimibe-simvastatin combination treatment on the 
carotid intima-media thickness was found in patients at 
high cardiovascular risk [4], as well as in patients with 
type 2 diabetes and no prior cardiovascular events [5], 
but not in patients with ischaemic heart disease or its 
equivalent [6] nor in patients with familial hypercho-
lesterolemia [7]. Moreover, although in patients with 
mild-to-moderate, asymptomatic aortic-valve stenosis, 
simvastatin-ezetimibe combination treatment reduced 
the incidence of ischaemic cardiovascular events, the 
treatment had no overall effect on the course of aortic-
valve stenosis [8].
The role of abnormal adipokine production in the 
pathophysiology of obesity, insulin resistance and 
cardiovascular diseases [9, 10] means that human 
adipose tissue seems to be an interesting target for 
hypolipidemic agents. In some studies [11–14], admin-
istration of HMG-CoA reductase inhibitors has led to 
an improvement in adipose tissue function, whereas 
other studies [15–18] did not find any effect of statins 
on plasma adipokines. Similarly, some authors have 
observed ezetimibe-induced changes in plasma adi-
pokines [19, 20], while other authors [16, 21, 22] have 
not found such a relationship. These results seem to 
indicate that the effect of statins and ezetimibe, admin-
istered alone, is relatively moderate. Our previous in 
vitro studies showed that the relatively weak effect of 
atorvastatin on adipokine release by cultures of whole 
adipose tissue [23] and cultures of isolated adipocytes 
[24] was much stronger if atorvastatin was administered 
together with fenofibric acid. These findings suggest 
that the combined hypolipidemic treatment may bring 
greater benefits to patients than the administration of 
only one hypolipidemic agent. Therefore, the aim of 
the present study was to investigate whether combi-
nation therapy with simvastatin and ezetimibe has 
an impact on plasma adipokine levels and low-grade 
systemic inflammation. Leptin, adiponectin, visfatin 
and TNF-α were chosen among different adipokines 
because they are important products of adipose tissue 
and their presence is found in atherosclerotic plaques, 
while abnormal levels are associated with an increased 
risk of atherosclerosis and its complications [25–27]. 
Also C-reactive protein (CRP), the best known marker 
of low-grade systemic inflammation, strongly and in-
dependently predicts adverse cardiovascular events, 
including myocardial infarction, ischaemic stroke, and 
sudden cardiac death [28, 29].
Material and methods
Patients (aged 35–60 years) were enrolled in the study 
if they met the following criteria: they were at high 
cardiovascular risk (ischaemic heart disease, SCORE 
at least 5, peripheral vascular disease and a history of 
stroke and/or transient ischaemic attacks), had isolated 
hypercholesterolemia defined as total plasma choles-
terol above 200 mg/dL, LDL cholesterol more than 
130 mg/dL and triglycerides below 150 mg/dL, and, in 
the case of women, they were at least 18 months since 
the last menstruation, hysterectomy or ovariectomy, or 
used barrier contraception. The exclusion criteria were 
as follows: any acute or chronic inflammatory processes, 
untreated stage 2 or 3 hypertension (according to the 
2003 European Society of Hypertension — European 
Society of Cardiology guidelines), symptomatic con-
gestive heart failure, diabetes, autoimmune disorders, 
thyroid diseases, chronic pancreatitis, impaired renal 
or hepatic function, body mass index above 35 kg/m2, 
and poor patient compliance. No patient had been 
treated with another hypolipidemic drug within the 
three months prior to the study or with drugs known 
to interfere with statins or ezetimibe. All participants 
(n = 19) provided written consent as approved by the 
ethics committee of the Medical University of Silesia. 
Each patient meeting the initial inclusion criteria 
received traditional counselling regarding diet and 
exercise in the form of printed material based on the 
National Cholesterol Education Programme diet and 
lifestyle recommendations. All enrolled patients were 
treated with simvastatin (40 mg daily) plus ezetimibe 
(10 mg daily), which were administered once daily 
for 30 days throughout the study. Our control group 
included 17 age-, sex- and weight-matched healthy 
subjects. The daily dose of simvastatin was the same as 
used in the Heart Protection Study, which is to date the 
largest study to investigate the use of statins in the pre-
vention of cardiovascular disease [30]. Throughout the 
entire study period, all patients complied with dietary 
recommendations. Compliance was assessed during 
each visit by pill count. Venous blood samples were 
drawn from the antecubital vein in a quiet, temperature-
controlled room (24–25°C) at a regular time each day 
(between 8:00 and 9:00 a.m.) at least 12 h after the last 
meal. Blood samples were also taken two hours after 
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a 75-g oral glucose load. To minimise analytical errors, 
all measurements were performed strictly according 
to the manufacturers’ instructions in duplicate within 
a single analytical session, and the final results were 
averaged. Plasma lipids (total cholesterol, LDL-cholesterol, 
HDL-cholesterol, and triglycerides) were assessed by 
a colorimetric method using commercial kits (bioMer-
ieux, France). LDL levels were measured directly. 
Plasma glucose concentrations were determined by 
a glucose oxidase method (Beckman, Palo Alto, CA, USA). 
Plasma insulin was measured with a commercial radio-
immunoassay kit (Linco Research Inc., St. Charles, MO, 
USA) that does not cross-react with human proinsulin. 
The homeostasis model assessment of insulin resistance 
(HOMA-IR) index was calculated from the following 
equation: fasting plasma glucose (mg/dL) × fasting in-
sulin level (mU/L)/405]. Total non-estrified free fatty 
acids (FFA) were determined by an enzymatic assay 
using reagents from Alpha Laboratories (Eastleigh, 
UK). Plasma levels of C-reactive protein (CRP) were 
measured using a high-sensitivity monoclonal antibody 
assay (MP Biomedicals, Orangeburg, NY, USA). Plasma 
levels of leptin, adiponectin, visfatin and TNF-α were 
measured with commercial enzyme-linked immuno-
sorbent assay kits obtained from TECOmedical Group 
(Sissach, Switzerland), Phoenix Pharmaceuticals (Burl-
ingame, CA, USA) and R&D Systems (Minneapolis, MN, 
USA). The minimum detectable levels for the assessed 
parameters were: 0.1 mg/L, 7.8 pg/mL, 0.246 ng/mL, 
6.1 pg/mL and 1.6 pg/mL respectively for hsCRP, leptin, 
adiponectin, visfatin and TNF-α. The intra- and interas-
say coefficients of variation for the assessed markers 
were less than 5.5 and 8.7%, respectively.
Different groups were compared using the t test for 
independent samples. Pretreatment and post-treatment 
data within the same group were compared with Stu-
dent’s paired t-test. For categorical variables, χ2 test 
was used. Correlations were calculated with the use 
of Kendall’s tau test. P less than 0.05 were regarded as 
statistically significant. 
Results
At the start of the study, there was no difference be-
tween the treatment and the control groups in terms 
of sex, weight, age and safety parameters. Plasma 
levels of adiponectin were lower, while plasma levels 
of leptin, visfatin, TNF-α, hsCRP and FFA, as well as 
HOMA-IR were higher, than in the control group. 
Demographic data and baseline results are shown 
in Table I. The treatment was well tolerated and, 
with the exception of one patient who developed 
abdominal pain and diarrhoea, all patients completed 
the study. In the control patients, circulating levels 
of lipids, glucose homeostasis markers, hsCRP and 
the investigated adipokines remained at a similar 
level throughout the study. Simvastatin adminis-
tered together with ezetimibe for 30 days decreased 
plasma levels of total cholesterol by 39% (p < 0.001) 
and LDL cholesterol by 45% (p < 0.001), tended to 
reduce HOMA-IR (–19%, p = 0.092), but did not af-
fect plasma triglycerides, HDL cholesterol, fasting 
and post-challenge plasma glucose (Table II). This 
therapy had also no effect on body mass index or 
waist circumference. Thirty days of the combined 
therapy decreased plasma levels of leptin by 38% 
(p < 0.001), visfatin by 29% (p < 0.05), TNF-α by 32% 
(p < 0.001), hsCRP by 39% (p < 0.001) and FFA by 
24% (p < 0.01), as well as increased circulating levels 
Table I. Baseline characteristics of participants1
Tabela I. Wyjściowa charakterystyka uczestników badania
Control group Combined treatment
Number of patients 17 18
Age [years; mean (SD)] 51.4 (2.7) 53.0 (3.7)
Women (%) 41 44
Smokers (%) 24 28
Body mass index  
[kg/m2; mean (SD)]
26.8 (2.9) 27.1 (2.4)
Waist circumference  
[cm; mean (SD)]
97 (4) 99 (5)
Intima-media thickness 
[mm; mean (SD)]
0.62 (0.11) 0.99 (0.11)***
Total cholesterol  
[mg/dL; mean (SD)]
160 (12) 261 (16)***
LDL cholesterol  
[mg/dL; mean (SD)]
96 (7) 188 (12)***
HDL cholesterol  
[mg/dL; mean (SD)]
50 (4) 46 (4)
Triglycerides  
[mg/dL; mean (SD)]
118 (11) 128 (12)
Fasting glucose  
[mg/dL; mean (SD)]
93 (5) 97 (5)
2-h post-challenge plasma 
glucose [mg/dL; mean (SD)]
128 (8) 137 (10)
HOMA-IR 1.2 (0.3) 2.6 (0.7)***
Free fatty acids  
[µmol/L; mean (SD)]
219 (42) 384 (57)***
hsCRP [mg/L; mean (SD)] 1.2 (0.2) 3.8 (0.7) ***
Leptin [ng/mL; mean (SD)] 10.8 (3.4) 25.8 (5.5)***
Adiponectin  
[mg/L; mean (SD)]
10.9 (1.3) 5.9 (1.1)***
Visfatin [ng/mL; mean (SD)] 10.1 (3.2) 21.8 (3.9)***
TNF-α [pg/mL; mean (SD)] 6.9 (1.6) 16.1 (2.6)***
1Only data of subjects who completed the study was included in the final 
analyses; ***p < 0.001 vs. control patients 
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of adiponectin by 97% (p < 0.001). At the end of the 
study period, plasma levels of leptin, visfatin, TNF-α, 
hsCRP and FFA were still higher than in the control 
group (Table III).
Baseline plasma levels of leptin, visfatin and TNF-α 
correlated positively with total cholesterol (r values 
between 0.40–0.52, p < 0.001), LDL cholesterol (r values 
between 0.43 and 0.58, p < 0.001), HOMA-IR (r values 
between 0.39 and 0.55, p < 0.001), and hsCRP (r values 
between 0,31 [p < 0.05] and 0.43 [p < 0.001]), as well as 
in the case of leptin and TNF-α with body mass index 
(r = 0.55, p < 0.001 for leptin; r = 0.34, p < 0.05 for 
TNF-α) and waist circumference (r = 0.49, p < 0.001 
for leptin; r = 0.32, p < 0.05 for TNF-α). Circulating 
adiponectin levels correlated negatively with body mass 
index, waist circumference, total and LDL cholesterol, 
HOMA-IR and hsCRP (r values between –0.37 [p < 0.01] 
and –0.56 [p < 0.001]). The treatment-induced changes 
in plasma adipokines correlated with the effect of treat-
ment on HOMA-IR (r values between 0.35 [p < 0.01] 
and 0.43 [p < 0.001]) and FFA (r values between 0.40 
and 0.52, p < 0.001). The treatment-induced reduction 
in plasma TNF-α correlated with the effect of treatment 
on plasma levels of the remaining adipokines (r values 
between 0.31 [p < 0.05] and 0.50 [p < 0.001]). There were 
correlations between the combined treatment-induced 
reduction in plasma hsCRP and the treatment-induced 
changes in plasma adipokines (r values between 0.41 
and 0.53, p < 0.001). No other correlations were found 
in either baseline conditions or after treatment.
Discussion
High-risk patients with elevated cholesterol levels were 
characterised by abnormal hormonal function of adipose 
tissue, which was parallelled by low-grade systemic 
inflammation. Taking into account that reduced plasma 
levels of leptin, visfatin and TNF-α, and increased 
circulating levels of adiponectin are considered inde-
pendent risk factors for cardiovascular disease [25–7], 
enhanced risk in this group of patients may be partially 
attributed to dysfunction of adipose tissue. Our study 
did not include high-risk patients with normal plasma 
lipids. However, the presence of correlations between 
baseline levels of adipokines and baseline total and LDL 
cholesterol levels, suggests that adipose tissue dysfunc-
Table II. The effect of simvastatin and ezetimibe treatment 
on plasma lipids and glucose homeostasis in patients with 
isolated hypercholesterolemia1
Tabela II. Wpływ simwastatyny i ezetimibu na stężenie 
w osoczu lipidów i homeostazę glukozy u pacjentów z 
izolowaną hipercholesterolemią
Control group 
Mean (SD)
Combined treatment 
Mean (SD)
Total cholesterol [mg/dL] 
Baseline value 
After 30 days
 
160 (12) 
157 (11)
 
261 (16)*** 
159 (14)###
LDL cholesterol [mg/dL] 
Baseline value 
After 30 days
 
96 (7) 
95 (7)
 
188 (12)*** 
102 (8) ###
HDL cholesterol [mg/dL] 
Baseline value 
After 30 days
 
50 (4) 
51 (4)
 
46 (4) 
51 (4)
Triglycerides [mg/dL] 
Baseline value 
After 30 days
 
118 (11) 
116 (12)
 
128 (12) 
114 (18)
Fasting glucose [mg/dL] 
Baseline value 
After 30 days
 
93 (5) 
92 (5)
 
97 (5) 
95 (4)
2-h post-challenge plasma 
glucose [mg/dL] 
Baseline value 
After 30 days
 
 
128 (8) 
126 (7)
 
 
137 (10) 
135 (10)
HOMA-IR  
Baseline value 
After 30 days
 
1.2 (0.3) 
1.3 (0.4)
 
2.6 (0.7)*** 
2.1 (0.5)***
1Only data of subjects who completed the study was included in the final 
analyses; ***p < 0.001 vs. control patients; ###p < 0.001 vs. baseline value
Table III. The effect of simvastatin and ezetimibe treatment 
on free fatty acids, hsCRP and adipokines in patients with 
isolated hypercholesterolemia1
Tabela III. Wpływ simwastatyny i ezetimibu na stężenie 
wolnych kwasów tłuszczowych, hsCRP i adipokin 
u pacjentów z izolowaną hipercholesterolemią
Control group 
Mean (SD)
Combined  
treatment 
Mean (SD)
Free fatty acids  
[µmol/L]  
Baseline value 
After 30 days
 
 
219 (42) 
208 (39)
 
 
384 (57)*** 
292 (41)***##
hsCRP [mg/L] 
Baseline value 
After 30 days
 
1.2 (0.2) 
1.3 (0.3)
 
3.8 (0.7)*** 
2.3 (0.5)***###
Leptin [ng/mL] 
Baseline value 
After 30 days
 
10.8 (3.4) 
10.4 (3.5)
 
25.8 (5.5)*** 
16.0 (3.8)*###
Adiponectin  
[mg/L] 
Baseline value 
After 30 days
 
10.9 (1.3) 
11.2 (1.2)
 
5.9 (1.1)*** 
11.6 (1.3)###
Visfatin [ng/mL] 
Baseline value 
After 30 days
 
10.1 (3.2) 
10.3 (2.7)
 
21.8 (3.9)*** 
15.5 (2.9)**#
TNF-α [pg/mL] 
Baseline value 
After 30 days
 
6.9 (1.6) 
7.0 (1.4)
 
16.1 (2.6)*** 
10.9 (2.4)***###
1Only data of subjects who completed the study was included in the final 
analyses; *p < 0.05; **p < 0.01 ; ***p < 0.001 vs. control patients; #p < 0.05; 
##p < 0.01; ###p < 0.001 vs. baseline value
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tion in high-risk patients without lipid abnormalities is 
less expressed than in the assessed population.
The aforementioned changes in plasma adipokines 
and hsCRP were alleviated by 30-day combined admin-
istration of both hypolipidemic agents. This finding 
indicates that the statin-ezetimibe combination causes 
early and multidirectional changes in adipose tissue 
function and reduces systemic inflammation, and that 
these effects of simvastatin plus ezetimibe are unrelated 
to lipid lowering. These findings are in line with a recent 
large clinical trial, which included 9,270 patients with 
chronic kidney disease with no known history of myo-
cardial infarction or coronary revascularisation, ran-
domised to simvastatin plus ezetimibe or to a placebo 
[31]. Simvastatin administered together with ezetimibe 
reduced the incidence of major atherosclerotic events 
(non-fatal myocardial infarction or coronary death, non-
haemorrhagic stroke, or any arterial revascularisation 
procedure) in this group of patients.
A partial normalisation of adipose tissue function 
in our patients cannot be attributed to the combined 
treatment-induced reduction in body fat content be-
cause both body mass index and waist circumference 
remained unaltered during the treatment. Nor can the 
changes in adipokine levels be explained by deteriora-
tion of kidney function [32] because there were no 
changes in glomerular filtration rate (data not shown). 
Therefore, our results most likely reflect the effect of the 
combined treatment on adipokine production and/or 
release by adipose tissue. 
The observations that plasma adipokine levels cor-
related with circulating hsCRP levels in both baseline 
conditions and after treatment shows that the combined 
treatment-induced improvement in adipose tissue 
function contributes to the systemic anti-inflammatory 
effect of this treatment. Interestingly, we have previ-
ously observed a similar relationship between the effect 
of simvastatin and ezetimibe on monocyte cytokine 
release [1], lymphocyte cytokine release [2] and haemo-
static cardiovascular risk factor [3] and their action on 
plasma hsCRP. Therefore, it may be safely assumed that 
the combined therapy-induced decrease in low-grade 
inflammation either is secondary to their action at the 
levels of various tissues, or that the anti-inflammatory 
effects of this drug normalise the function of various 
organs.
At the end of the treatment period, with the ex-
ception of adiponectin, plasma adipokine levels, free 
fatty acids and hsCRP were still different from those 
observed in the control group, although plasma lipid 
levels were similar to those observed in the healthy 
subjects. The obtained results suggest that a treatment 
period longer than that used in the present study would 
produce a stronger inhibitory effect on adipose tissue 
and systemic inflammation, and that a certain minimal 
period of treatment is required to exhibit the full efficacy 
of the statin-ezetimibe combination in the prevention 
and treatment of atherosclerosis-related diseases.
Interestingly, the effect of the treatment on plasma 
adipokines correlated with the action of simvastatin 
plus ezetimibe on HOMA-IR. The link between the 
action of simvastatin and ezetimibe on adipokines 
and on insulin sensitivity is further supported by 
finding the correlations between treatment-induced 
changes in plasma adipokines and in FFA, as well as 
the correlations between the effect of treatment on 
leptin, adiponectin and visfatin and on TNF-α. It is 
worth underlining that FFA [33] and TNF-α [34], by 
impairing insulin receptor action, are implicated in 
the development of insulin resistance. These obser-
vations may suggest that either adipokines mediate 
the effect of the combined treatment on insulin sen-
sitivity, or that the normalisation of adipose tissue 
function is a consequence of a reduction in insulin 
resistance. 
There are several limitations of this study, the most 
important of which are the small sample size and the 
lack of a reference group treated only with a statin or 
ezetimibe. Moreover, we measured only surrogate end-
points. Finally, plasma adipokine levels do not seem to 
accurately reflect adipokine secretion by different types 
of adipose tissue.
To sum up, our study has revealed that high-risk 
patients with isolated hypercholesterolemia are char-
acterised by abnormal adipokine production and the 
presence of low-grade inflammation. Thirty days of the 
combined treatment partially reversed adipose tissue 
dysfunction and reduced systemic inflammation, and 
therefore the simvastatin-ezetimibe combination may 
bring some benefits to the investigated population of 
patients.
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